‘There are four main challenges that must be addressed as soon as possible if a vaccine is to be produced quickly and at a large scale. (1) Existing manufacturing capacity is limited (2) The type of vaccine is still unknown (3) The size of the problem is unprecedented (4) “Economic poker game” of seeking to minimize costs and maximize revenue.’
Read here (IPS News, August 25, 2020)
